Table 1. Patient baseline characteristics.
|
Docetaxel alone (arm A) (n=44)
|
Docetaxel–gemcitabine (3-weekly) (arm B) (n=44)
|
Docetaxel–gemcitabine (weekly) (arm C) (n=44)
|
||||
|---|---|---|---|---|---|---|
| % | Count | % | Count | % | Count | |
| Residual bulk | ||||||
| None/micro | 36.4 | 16 | 34.1 | 15 | 36.4 | 16 |
| ⩽2 cm | 29.5 | 13 | 27.3 | 12 | 29.5 | 13 |
| >2 cm | 34.1 | 15 | 38.6 | 17 | 34.1 | 15 |
| FIGO stage | ||||||
| Ic | 4.5 | 2 | 6.8 | 3 | 6.8 | 3 |
| II | 15.9 | 7 | 9.1 | 4 | 11.4 | 5 |
| III | 65.9 | 29 | 70.5 | 31 | 68.2 | 30 |
| IV | 13.6 | 6 | 13.6 | 6 | 13.6 | 6 |
| Tumour grade | ||||||
| Well | 9.1 | 4 | 2.3 | 1 | 4.5 | 2 |
| Moderate | 25.0 | 11 | 25.0 | 11 | 27.3 | 12 |
| Poor | 56.8 | 25 | 61.4 | 27 | 56.8 | 25 |
| Unknown | 9.1 | 4 | 11.4 | 5 | 11.4 | 5 |
| ECOG PS | ||||||
| 0 | 36.4 | 16 | 38.6 | 17 | 38.6 | 17 |
| 1 | 59.1 | 26 | 54.5 | 24 | 54.5 | 24 |
| 2 | 4.5 | 2 | 6.8 | 3 | 6.8 | 3 |
| Intent to have debulking operation | ||||||
| No | 81.8 | 36 | 84.1 | 37 | 81.8 | 36 |
| Yes | 18.2 | 8 | 15.9 | 7 | 18.2 | 8 |
| Cancer type | ||||||
| Ovarian | 90.9 | 40 | 90.9 | 40 | 90.9 | 40 |
| Peritoneal | 6.8 | 3 | 6.8 | 3 | 9.1 | 4 |
| Fallopian | 2.3 | 1 | 2.3 | 1 | 0.0 | 0 |
| CA-125>ULN prior to chemotherapy | ||||||
| No | 11.4 | 5 | 18.2 | 8 | 13.6 | 6 |
| Yes | 88.6 | 39 | 81.8 | 36 | 86.4 | 38 |
CA-125=cancer antigen 125; ECOG PS=Eastern Cooperative Oncology Group Performance Status; FIGO=International Federation of Gynecologic Oncology; ULN=upper limit of normal.